Capital World Investors Invests $67.89 Million in Ralliant Corporation $RAL

Key Points

• Capital World Investors bought a new stake of 1,552,364 shares in Ralliant (≈$67.89 million), giving it about a 1.38% ownership position.
• Ralliant beat Q4 estimates with $0.69 EPS (vs. $0.67 est.) and $554.6M revenue, set Q1 2026 guidance of 0.460–0.520 EPS and FY2026 guidance of 2.220–2.420 EPS, and declared a $0.05 quarterly dividend (0.5% yield) while the stock traded down ~6.6% and carries a consensus "Hold" with a $50.50 price target.
• Insiders were active: Director Anelise Angelino Sacks bought 2,000 shares at $41.25, SVP Karen M. Bick sold 5,485 shares at $45, and insiders have net acquired 8,145 shares (~$332,233) in the last 90 days.

Capital World Investors acquired a new stake in Ralliant Corporation (NYSE:RAL - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,552,364 shares of the company's stock, valued at approximately $67,885,000. Capital World Investors owned approximately 1.38% of Ralliant as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vestcor Inc lifted its holdings in shares of Ralliant by 315.8% in the third quarter. Vestcor Inc now owns 10,378 shares of the company's stock worth $454,000 after acquiring an additional 7,882 shares during the last quarter. Clarkston Capital Partners LLC grew its holdings in shares of Ralliant by 200.1% during the 3rd quarter. Clarkston Capital Partners LLC now owns 566,405 shares of the company's stock valued at $24,769,000 after purchasing an additional 377,652 shares during the last quarter. Russell Investments Group Ltd. increased its position in Ralliant by 443.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 164,276 shares of the company's stock worth $7,184,000 after purchasing an additional 134,065 shares in the last quarter. Schroder Investment Management Group acquired a new position in Ralliant during the 3rd quarter worth approximately $380,000. Finally, Private Advisor Group LLC bought a new position in Ralliant in the 3rd quarter valued at approximately $223,000.

Insider Transactions at Ralliant

In other news, Director Anelise Angelino Sacks acquired 2,000 shares of Ralliant stock in a transaction dated Monday, February 9th. The shares were bought at an average cost of $41.25 per share, with a total value of $82,500.00. Following the purchase, the director owned 5,403 shares in the company, valued at $222,873.75. This trade represents a 58.77% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Karen M. Bick sold 5,485 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the sale, the senior vice president owned 46,756 shares of the company's stock, valued at approximately $2,104,020. This trade represents a 10.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have acquired 8,145 shares of company stock worth $332,233.

Ralliant Stock Down 6.6%

Shares of RAL opened at $42.77 on Friday. The stock's 50-day moving average price is $48.42 and its two-hundred day moving average price is $46.69. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $57.02. The company has a market capitalization of $4.78 billion and a PE ratio of 21.82. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a yield of 0.5%. Ralliant's dividend payout ratio (DPR) is presently 10.20%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RAL shares. Zacks Research lowered shares of Ralliant from a "hold" rating to a "strong sell" rating in a research report on Monday, February 9th. Weiss Ratings cut Ralliant from a "hold (c)" rating to a "sell (d)" rating in a research note on Thursday, February 5th. Oppenheimer cut their price objective on Ralliant from $60.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, February 6th. Citigroup reduced their price objective on Ralliant from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, February 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $45.00 target price on shares of Ralliant in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $50.50.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.